Warning letter
Jajco, Inc. DBA Anchor Drugs Pharmacy: warning letter of Aug 22, 2017
FDA warning letter 522517 · Los Angeles District Office
Key facts
| Reference number | 522517 |
|---|---|
| Company | Jajco, Inc. DBA Anchor Drugs Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Aug 22, 2017 |
| Posted date | Nov 7, 2017 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 210.1(b), 211.113(b), 211.166(a), 211.192, 200.10(b), 211.28(a), 211.42(c)(10)(iii), 211.42(c)(10)(iv), 211.42(c)(10)(v) |
| Inspection city | South San Francisco |
| Inspection ZIP | 94080 |
| Inspection start date | May 20, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: